Targeting EGFR and sonic hedgehog pathways for locally advanced eyelid and periocular carcinomas

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Eyelid and periocular carcinomas present challenges for surgical excision, especially in advanced or metastatic stages.
• Cytotoxic chemotherapy offers limited efficacy and tolerability for these patients.
• Epithelial growth factor receptor (EGFR) overexpression is noted in squamous cell carcinomas.

Purpose of the Study:

• To evaluate the efficacy and tolerability of targeted therapies for eyelid and periocular carcinoma.
• To identify potential targeted agents for patients unsuitable for surgery.

Main Methods:

• Review of targeted therapies, including vismodegib, for eyelid and periocular carcinoma.
• Analysis of pathway mutations (e.g., hedgehog pathway in basal cell carcinoma) and receptor overexpression (e.g., EGFR).

Main Results:

• Targeted therapies demonstrate efficacy and improved tolerability compared to traditional chemotherapy.
• Vismodegib targets specific mutations in the hedgehog pathway relevant to basal cell carcinoma.
• Eyelid carcinomas, particularly squamous cell types, may overexpress EGFR.

Conclusions:

• Targeted therapies represent a novel and effective treatment option for unresectable eyelid and periocular carcinoma.
• These therapies benefit patients with metastatic, locally advanced disease, elderly patients, and those with comorbidities.
• Limitations include high cost, need for long-term administration, and potential toxicities.